Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
EARLY_PHASE1
22
about 1.1 years
18–80
1 site in CT
About this study
This trial is testing a new imaging drug called [18F]MK-0947 to see if it can help doctors visualize changes in the brain related to Parkinson's disease (PD). The drug works with PET scans to show areas of the brain where α-synuclein builds up, which is linked to PD. The trial aims to determine if [18F]MK-0947 is safe and effective for visualizing α-synuclein in the brain.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take [18F]MK-0947
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Safety of [18F]MK-0947: Incidence of Adverse Events
Secondary: Model-derived Pharmacokinetics of [18F]MK-0947
Neurology